News & Insights

The mission of the Global Health Technologies Coalition (GHTC) is to accelerate the creation of new drugs, vaccines, diagnostics, and other health tools to bring healthy lives within reach for all people. The next Administration and Congress will have the opportunity to catalyze a new era of biomedical innovation through investing in the United States’ global health research and development (R&D) apparatus, which is underpinned by the lifesaving work happening at the US Agency for International Development, National Institutes of Health, Biomedical Advanced Research and Development Authority, Centers for Disease Control and Prevention, and many other government entities. This new era could tackle legacy issues of malaria, tuberculosis, and HIV/AIDS; shift the balance in the fight against antimicrobial resistance; and prepare us for new and emerging health threats at home and abroad. At this crucial pivot point, GHTC stands ready to work with decision-makers of both parties to ensure US support for global health R&D remains integral to US foreign and domestic policy. GHTC is committed to ensuring that the gains we have already made on neglected and emerging health challenges are not only sustained but also strengthened to combat a more troubling and evolving health landscape. We know strong support for global health R&D is central to our country’s national security, diplomatic efforts, and economic interests. But above all, US support to create the next generation of global health technologies saves lives and bolsters the health and well-being of everyone everywhere.  GHTC will continue to work with our more than 45 member organizations to articulate these needs to the new slate of political leaders and reinvigorate the United States’ role as a global health leader.

The Global Health Technologies Coalition (GHTC) welcomes yesterday’s G20 Health Ministers’ Declaration, as well as their Declaration on Climate Change, Health and Equity, and on One Health, which elevates the importance of investments in new tools and technologies to fight infectious diseases—work that can be broadly beneficial in confronting a wide range of health threats.It was encouraging to see G20 leaders offer such strong support to the Pandemic Fund, the intergovernmental negotiating body process on a pandemic accord, and the International Health Regulations amendments made earlier this year.   GHTC strongly supports the establishment of a Coalition for Local and Regional Production, Innovation and Equitable Access centered on voluntary cooperation to promote access to vaccines, therapeutics, diagnostics, and other health technologies for neglected and infectious diseases. We are pleased to see that the health ministerial declaration explicitly highlights the need for this coalition to promote synergies with existing and potential future initiatives and to work with a wide range of stakeholders. We appreciate that there are specific callouts supporting the efforts of several of our members and partners, including the Coalition for Epidemic Preparedness Innovations; Gavi, the Vaccine Alliance, and its African Vaccine Manufacturing Accelerator initiative; the Regionalized Vaccine Manufacturing Collaborative; the Pandemic Fund; PATH; Drugs for Neglected Diseases initiative; Stop TB; Global Fund; UNITAID; and Medicines Patent Pool.   While the creation of the coalition is an encouraging step forward, we urge G20 nations to consider additional ways to strengthen local research capacity, including through support for research and development (R&D) hubs, distributed manufacturing, and clinical trial infrastructure in low- and middle-income countries. We also would have liked to see a stronger emphasis on equity throughout the health ministerial declaration—not just in some sections—emphasizing the urgency to address the specific needs of women, children, and other underserved populations.   Beyond placing a strong focus on local production, the Brazilian G20 presidency also elevated the linkages between climate, health, and antimicrobial resistance (AMR) this year. It was encouraging to see the health equity and climate change declaration call on G20 nations to encourage and promote health R&D and stronger, more transparent partnerships between the public and the private sectors, as well as academia, affected communities, and the scientific community.   We also welcome the continued support highlighted in the health equity and climate change declaration for initiatives such as the Global AMR R&D Hub, the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator, the Global Antibiotic Research and Development Partnership, and the International Centre for Antimicrobial Resistance Solutions. Furthermore, we appreciate the declaration’s continued support for regional organizations that guide research, development, and strategies to accelerate new AMR health technologies and alternatives to the use of antimicrobials, promote equitable access and global stewardship, and maximize public investment returns. We are pleased that the declaration also emphasizes the importance of promoting equitable access to new tools, including through programs like the World Health Organization AWaRe classification of antibiotics.   We applaud G20 leaders for underscoring the linkages between AMR and the ongoing malaria, tuberculosis, and HIV/AIDS epidemics, stressing the need to break down silos. However, it is disappointing to see no commitments or robust support for the financing of AMR, whether through push-pull incentive models or other specific initiatives.   As always, we urge G20 members to work with civil society to push for the successful implementation of these key principles, pledges, and initiatives, and we hope that all relevant stakeholders will work diligently toward increasing access to health technologies.